You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzphetamine
Accession NumberDB00865  (APRD00759)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Structure
Thumb
Synonyms
(+)-benzphetamine
(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(+)-N-benzyl-N,α-dimethylphenethylamine
(+)-N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine
(+)-N,α-dimethyl-N-(phenylmethyl)-benzeneethanamine
(AlphaS)-N,alpha-dimethylphenethylamine
(S)-(+)-benzphetamine
(S)-(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(S)-(+)-N-benzyl-N,α-dimethylphenethylamine
(S)-benzphetamine
Benzaphetamine
Benzfetamina
Benzfetamine
Benzfetaminum
Benzphetamine
Benzylamphetamine
D-N-Methyl-N-benzyl-beta-phenylisopropylamine
d-N-methyl-N-benzyl-β-phenylisopropylamine
N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Didrextablet50 mg/1oralA S Medication Solutions Llc1960-10-26Not applicableUs
Didrextablet50 mg/1oralA S Medication Solutions Llc1960-10-26Not applicableUs
Didrextablet50 mg/1oralPd Rx Pharmaceuticals, Inc.1960-10-26Not applicableUs
Didrextablet50 mg/1oralPharmacia and Upjohn Company1960-10-262015-12-29Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benzphetaminetablet25 mg/1oralTedor Pharma Inc.2016-02-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2011-11-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralBoca Pharmacal, LLC2010-09-07Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-12-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet, film coated50 mg/1oralHeritage Pharmaceuticals Inc.2012-10-19Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralC.O. Truxton, Inc.2011-11-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralAidarex Pharmaceuticals LLC2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralSolco Healthcare US LLC2011-08-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralKvk Tech, Inc2010-07-21Not applicableUs
Benzphetamine Hydrochloridetablet25 mg/1oralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-09Not applicableUs
Benzphetamine Hydrochloridetablet, film coated50 mg/1oralEpic Pharma, LLC2015-12-16Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralMikart, Inc.2011-11-01Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralApotheca Inc.2009-12-09Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine Hydrochloridetablet50 mg/1oralbryant ranch prepack2010-02-01Not applicableUs
Regimextablet25 mg/1oralWraser Pharmaceuticals2013-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Benzphetamine Hydrochloride
Thumb
  • InChI Key: ANFSNXAXVLRZCG-UHFFFAOYNA-N
  • Monoisotopic Mass: 275.144077416
  • Average Mass: 275.816
DBSALT000832
Categories
UNII0M3S43XK27
CAS number156-08-1
WeightAverage: 239.3553
Monoisotopic: 239.167399677
Chemical FormulaC17H21N
InChI KeyInChIKey=YXKTVDFXDRQTKV-HNNXBMFYSA-N
InChI
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
IUPAC Name
benzyl(methyl)[(2S)-1-phenylpropan-2-yl]amine
SMILES
C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
PharmacodynamicsBenzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism of actionAlthough the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.
Related Articles
AbsorptionReadily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Volume of distributionNot Available
Protein binding75-99%
Metabolism

Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine.

SubstrateEnzymesProduct
Benzphetamine
Not Available
AmphetamineDetails
Benzphetamine
Not Available
MethamphetamineDetails
Route of eliminationNot Available
Half life16 to 31 hours
ClearanceNot Available
ToxicityLD50=160 mg/kg (orally in rats). Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9864
Caco-2 permeable+0.8815
P-glycoprotein substrateSubstrate0.541
P-glycoprotein inhibitor INon-inhibitor0.8803
P-glycoprotein inhibitor IINon-inhibitor0.9437
Renal organic cation transporterInhibitor0.7013
CYP450 2C9 substrateNon-substrate0.769
CYP450 2D6 substrateNon-substrate0.588
CYP450 3A4 substrateNon-substrate0.5135
CYP450 1A2 substrateInhibitor0.8684
CYP450 2C9 inhibitorNon-inhibitor0.9146
CYP450 2D6 inhibitorInhibitor0.539
CYP450 2C19 inhibitorNon-inhibitor0.5997
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8047
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.6584
BiodegradationNot ready biodegradable0.9825
Rat acute toxicity3.1442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.5331
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Corepharma llc
  • Impax laboratories inc
  • Kvk tech inc
  • Paddock laboratories inc
  • Tedor pharma inc
  • Tyco healthcare mallinckrodt
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Tabletoral50 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral25 mg/1
Prices
Unit descriptionCostUnit
Didrex 50 mg tablet1.71USD tablet
Benzphetamine hcl 50 mg tablet1.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129-130Heinzelman, R.V. and Aspergren, B.D.; US. Patent 2,789,138; April 16,1957; assigned to The Upjohn Company.
water solubilityReadily solubleNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0233 mg/mLALOGPS
logP3.72ALOGPS
logP4.34ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity78.39 m3·mol-1ChemAxon
Polarizability29.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Dennis J. Kalota, Keith G. Tomazi, “Crystallization Method for Benzphetamine.” U.S. Patent US20080262268, issued October 23, 2008.

US20080262268
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (16.6 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Benzphetamine.
AcebutololThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Acebutolol.
AcepromazineAcepromazine may decrease the stimulatory activities of Benzphetamine.
AceprometazineAceprometazine may decrease the stimulatory activities of Benzphetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Benzphetamine.
AcrivastineBenzphetamine may decrease the sedative activities of Acrivastine.
AlcaftadineBenzphetamine may decrease the sedative activities of Alcaftadine.
AlfentanilBenzphetamine may increase the analgesic activities of Alfentanil.
AlimemazineBenzphetamine may decrease the sedative activities of Alimemazine.
AlphacetylmethadolBenzphetamine may increase the analgesic activities of Alphacetylmethadol.
AlprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmineptineAmineptine may increase the stimulatory activities of Benzphetamine.
AmiodaroneThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.
AmisulprideAmisulpride may decrease the stimulatory activities of Benzphetamine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Benzphetamine.
Ammonium chlorideThe serum concentration of Benzphetamine can be decreased when it is combined with Ammonium chloride.
AmperozideAmperozide may decrease the stimulatory activities of Benzphetamine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Benzphetamine.
AntazolineBenzphetamine may decrease the sedative activities of Antazoline.
AprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may decrease the stimulatory activities of Benzphetamine.
ArotinololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
AsenapineAsenapine may decrease the stimulatory activities of Benzphetamine.
AstemizoleBenzphetamine may decrease the sedative activities of Astemizole.
AtazanavirThe metabolism of Benzphetamine can be decreased when combined with Atazanavir.
AtenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.
AtomoxetineAtomoxetine may increase the hypertensive activities of Benzphetamine.
AzaperoneAzaperone may decrease the stimulatory activities of Benzphetamine.
AzatadineBenzphetamine may decrease the sedative activities of Azatadine.
AzelastineBenzphetamine may decrease the sedative activities of Azelastine.
BefunololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenmoxinBenmoxin may increase the hypertensive activities of Benzphetamine.
BetaxololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Benzphetamine can be decreased when it is combined with Bexarotene.
BezitramideBenzphetamine may increase the analgesic activities of Bezitramide.
BifeprunoxBifeprunox may decrease the stimulatory activities of Benzphetamine.
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BisoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BoceprevirThe metabolism of Benzphetamine can be decreased when combined with Boceprevir.
BopindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Benzphetamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Benzphetamine.
BrompheniramineBenzphetamine may decrease the sedative activities of Brompheniramine.
BuclizineBenzphetamine may decrease the sedative activities of Buclizine.
BufuralolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineBenzphetamine may increase the analgesic activities of Buprenorphine.
Butanoic AcidBenzphetamine may decrease the sedative activities of Butanoic Acid.
ButorphanolBenzphetamine may increase the analgesic activities of Butorphanol.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
CarbamazepineThe metabolism of Benzphetamine can be increased when combined with Carbamazepine.
CarbinoxamineBenzphetamine may decrease the sedative activities of Carbinoxamine.
CarfentanilBenzphetamine may increase the analgesic activities of Carfentanil.
CariprazineCariprazine may decrease the stimulatory activities of Benzphetamine.
CaroxazoneCaroxazone may increase the hypertensive activities of Benzphetamine.
CarteololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CeliprololThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Celiprolol.
CeritinibThe serum concentration of Benzphetamine can be increased when it is combined with Ceritinib.
CetirizineBenzphetamine may decrease the sedative activities of Cetirizine.
ChloropyramineBenzphetamine may decrease the sedative activities of Chloropyramine.
ChlorphenamineBenzphetamine may decrease the sedative activities of Chlorphenamine.
ChlorphenoxamineBenzphetamine may decrease the sedative activities of Chlorphenoxamine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Chlorphentermine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Benzphetamine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Benzphetamine.
CimetidineBenzphetamine may decrease the sedative activities of Cimetidine.
CinnarizineBenzphetamine may decrease the sedative activities of Cinnarizine.
CitalopramThe metabolism of Benzphetamine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.
ClemastineBenzphetamine may decrease the sedative activities of Clemastine.
ClemastineThe metabolism of Benzphetamine can be decreased when combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Clenbuterol.
ClomipramineClomipramine may increase the stimulatory activities of Benzphetamine.
ClopidogrelThe metabolism of Benzphetamine can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Benzphetamine can be decreased when combined with Clotrimazole.
ClozapineClozapine may decrease the stimulatory activities of Benzphetamine.
CobicistatThe metabolism of Benzphetamine can be decreased when combined with Cobicistat.
CodeineBenzphetamine may increase the analgesic activities of Codeine.
ConivaptanThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Benzphetamine can be decreased when combined with Crizotinib.
CyamemazineCyamemazine may decrease the stimulatory activities of Benzphetamine.
CyclizineBenzphetamine may decrease the sedative activities of Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Benzphetamine.
CyclosporineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.
CyproheptadineBenzphetamine may decrease the sedative activities of Cyproheptadine.
DabrafenibThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.
DapiprazoleDapiprazole may decrease the stimulatory activities of Benzphetamine.
DarunavirThe metabolism of Benzphetamine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Benzphetamine can be decreased when combined with Delavirdine.
DesipramineDesipramine may increase the stimulatory activities of Benzphetamine.
DesloratadineBenzphetamine may decrease the sedative activities of Desloratadine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Benzphetamine.
DexamethasoneThe serum concentration of Benzphetamine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineBenzphetamine may decrease the sedative activities of Dexbrompheniramine.
Dexchlorpheniramine maleateBenzphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
DextromoramideBenzphetamine may increase the analgesic activities of Dextromoramide.
DextropropoxypheneBenzphetamine may increase the analgesic activities of Dextropropoxyphene.
DezocineBenzphetamine may increase the analgesic activities of Dezocine.
DiclofenamideDiclofenamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DihydrocodeineBenzphetamine may increase the analgesic activities of Dihydrocodeine.
DihydroergotamineThe metabolism of Benzphetamine can be decreased when combined with Dihydroergotamine.
DihydroetorphineBenzphetamine may increase the analgesic activities of Dihydroetorphine.
DihydromorphineBenzphetamine may increase the analgesic activities of Dihydromorphine.
DiltiazemThe metabolism of Benzphetamine can be decreased when combined with Diltiazem.
DimenhydrinateBenzphetamine may decrease the sedative activities of Dimenhydrinate.
DimetindeneBenzphetamine may decrease the sedative activities of Dimetindene.
DimetotiazineBenzphetamine may decrease the sedative activities of Dimetotiazine.
DiphenhydramineBenzphetamine may decrease the sedative activities of Diphenhydramine.
DiphenoxylateBenzphetamine may increase the analgesic activities of Diphenoxylate.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Benzphetamine.
DopamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dopamine.
DosulepinDosulepin may increase the stimulatory activities of Benzphetamine.
DoxepinBenzphetamine may decrease the sedative activities of Doxepin.
DoxepinDoxepin may increase the stimulatory activities of Benzphetamine.
DoxofyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxofylline.
DoxorubicinThe metabolism of Benzphetamine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Benzphetamine can be decreased when combined with Doxycycline.
DoxylamineBenzphetamine may decrease the sedative activities of Doxylamine.
DPDPEBenzphetamine may increase the analgesic activities of DPDPE.
DronabinolDronabinol may increase the tachycardic activities of Benzphetamine.
DronedaroneThe metabolism of Benzphetamine can be decreased when combined with Dronedarone.
DroperidolDroperidol may decrease the stimulatory activities of Benzphetamine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Benzphetamine.
EfavirenzThe serum concentration of Benzphetamine can be decreased when it is combined with Efavirenz.
EmedastineBenzphetamine may decrease the sedative activities of Emedastine.
EnzalutamideThe serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.
EphedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ephedrine.
EpinastineBenzphetamine may decrease the sedative activities of Epinastine.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Benzphetamine.
ErythromycinThe metabolism of Benzphetamine can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Benzphetamine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineBenzphetamine may decrease the sedative activities of Esmirtazapine.
EsmirtazapineEsmirtazapine may increase the stimulatory activities of Benzphetamine.
EsmololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.
EthopropazineBenzphetamine may decrease the sedative activities of Ethopropazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
EthylmorphineBenzphetamine may increase the analgesic activities of Ethylmorphine.
EtilefrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Etilefrine.
EtorphineBenzphetamine may increase the analgesic activities of Etorphine.
EtravirineThe serum concentration of Benzphetamine can be decreased when it is combined with Etravirine.
FamotidineBenzphetamine may decrease the sedative activities of Famotidine.
FencamfamineFencamfamine may decrease the stimulatory activities of Benzphetamine.
FenoterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fenoterol.
FentanylBenzphetamine may increase the analgesic activities of Fentanyl.
FexofenadineBenzphetamine may decrease the sedative activities of Fexofenadine.
FluconazoleThe metabolism of Benzphetamine can be decreased when combined with Fluconazole.
FlunarizineBenzphetamine may decrease the sedative activities of Flunarizine.
FlupentixolFlupentixol may decrease the stimulatory activities of Benzphetamine.
FluphenazineFluphenazine may decrease the stimulatory activities of Benzphetamine.
FluspirileneFluspirilene may decrease the stimulatory activities of Benzphetamine.
FluvoxamineThe metabolism of Benzphetamine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Benzphetamine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Benzphetamine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypertensive activities of Benzphetamine.
Fusidic AcidThe serum concentration of Benzphetamine can be increased when it is combined with Fusidic Acid.
GuanethidineThe serum concentration of Benzphetamine can be decreased when it is combined with Guanethidine.
HaloperidolHaloperidol may decrease the stimulatory activities of Benzphetamine.
HeroinBenzphetamine may increase the analgesic activities of Heroin.
HexamethylenetetramineThe serum concentration of Benzphetamine can be decreased when it is combined with Hexamethylenetetramine.
HydracarbazineHydracarbazine may increase the hypertensive activities of Benzphetamine.
HydrocodoneBenzphetamine may increase the analgesic activities of Hydrocodone.
HydromorphoneBenzphetamine may increase the analgesic activities of Hydromorphone.
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hydroxyamphetamine hydrobromide.
HydroxyzineBenzphetamine may decrease the sedative activities of Hydroxyzine.
IdelalisibThe serum concentration of Benzphetamine can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may decrease the stimulatory activities of Benzphetamine.
ImatinibThe metabolism of Benzphetamine can be decreased when combined with Imatinib.
ImipramineImipramine may increase the stimulatory activities of Benzphetamine.
IndenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe metabolism of Benzphetamine can be decreased when combined with Indinavir.
Ioflupane I-123Benzphetamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the hypertensive activities of Benzphetamine.
IproniazidIproniazid may increase the hypertensive activities of Benzphetamine.
IsavuconazoniumThe metabolism of Benzphetamine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Benzphetamine.
IsoprenalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.
IsothipendylBenzphetamine may decrease the sedative activities of Isothipendyl.
IsoxsuprineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoxsuprine.
IsradipineThe metabolism of Benzphetamine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Benzphetamine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Benzphetamine can be increased when it is combined with Ivacaftor.
KetobemidoneBenzphetamine may increase the analgesic activities of Ketobemidone.
KetoconazoleThe metabolism of Benzphetamine can be decreased when combined with Ketoconazole.
KetotifenBenzphetamine may decrease the sedative activities of Ketotifen.
L-Glutamic AcidThe serum concentration of Benzphetamine can be decreased when it is combined with L-Glutamic Acid.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Benzphetamine.
LevocabastineBenzphetamine may decrease the sedative activities of Levocabastine.
LevocetirizineBenzphetamine may decrease the sedative activities of Levocetirizine.
Levomethadyl AcetateBenzphetamine may increase the analgesic activities of Levomethadyl Acetate.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Benzphetamine.
LevorphanolBenzphetamine may increase the analgesic activities of Levorphanol.
LinezolidLinezolid may increase the hypertensive activities of Benzphetamine.
LithiumLithium may decrease the stimulatory activities of Benzphetamine.
LodoxamideBenzphetamine may decrease the sedative activities of Lodoxamide.
LofentanilBenzphetamine may increase the analgesic activities of Lofentanil.
LopinavirThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.
LoratadineBenzphetamine may decrease the sedative activities of Loratadine.
LovastatinThe metabolism of Benzphetamine can be decreased when combined with Lovastatin.
LoxapineLoxapine may decrease the stimulatory activities of Benzphetamine.
LuliconazoleThe serum concentration of Benzphetamine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Benzphetamine can be decreased when it is combined with Lumacaftor.
LurasidoneLurasidone may decrease the stimulatory activities of Benzphetamine.
MagaldrateMagaldrate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MebanazineMebanazine may increase the hypertensive activities of Benzphetamine.
MeclizineBenzphetamine may decrease the sedative activities of Meclizine.
MelperoneMelperone may decrease the stimulatory activities of Benzphetamine.
MephentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.
MepyramineBenzphetamine may decrease the sedative activities of Mepyramine.
MequitazineBenzphetamine may decrease the sedative activities of Mequitazine.
MesoridazineMesoridazine may decrease the stimulatory activities of Benzphetamine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Benzphetamine.
MethadoneBenzphetamine may increase the analgesic activities of Methadone.
Methadyl AcetateBenzphetamine may increase the analgesic activities of Methadyl Acetate.
MethamphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methamphetamine.
MethapyrileneBenzphetamine may decrease the sedative activities of Methapyrilene.
MethazolamideMethazolamide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Benzphetamine.
Methylene blueMethylene blue may increase the hypertensive activities of Benzphetamine.
MetiamideBenzphetamine may decrease the sedative activities of Metiamide.
MetoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.
MianserinThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Mianserin.
MianserinBenzphetamine may decrease the sedative activities of Mianserin.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Benzphetamine.
MifepristoneThe metabolism of Benzphetamine can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may decrease the antihypertensive activities of Benzphetamine.
MinaprineMinaprine may increase the hypertensive activities of Benzphetamine.
MirtazapineBenzphetamine may decrease the sedative activities of Mirtazapine.
MirtazapineMirtazapine may increase the stimulatory activities of Benzphetamine.
MitotaneThe serum concentration of Benzphetamine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypertensive activities of Benzphetamine.
ModafinilThe serum concentration of Benzphetamine can be decreased when it is combined with Modafinil.
MolindoneMolindone may decrease the stimulatory activities of Benzphetamine.
MorphineBenzphetamine may increase the analgesic activities of Morphine.
NabiloneNabilone may increase the tachycardic activities of Benzphetamine.
NadololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
NafcillinThe serum concentration of Benzphetamine can be decreased when it is combined with Nafcillin.
NalbuphineBenzphetamine may increase the analgesic activities of Nalbuphine.
NefazodoneThe metabolism of Benzphetamine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Benzphetamine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Benzphetamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Benzphetamine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypertensive activities of Benzphetamine.
NilotinibThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.
NizatidineBenzphetamine may decrease the sedative activities of Nizatidine.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Benzphetamine.
NormethadoneBenzphetamine may increase the analgesic activities of Normethadone.
NortriptylineNortriptyline may increase the stimulatory activities of Benzphetamine.
NylidrinThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.
OctamoxinOctamoxin may increase the hypertensive activities of Benzphetamine.
OlanzapineOlanzapine may decrease the stimulatory activities of Benzphetamine.
OlaparibThe metabolism of Benzphetamine can be decreased when combined with Olaparib.
OlopatadineBenzphetamine may decrease the sedative activities of Olopatadine.
OndansetronOndansetron may decrease the stimulatory activities of Benzphetamine.
OpiumBenzphetamine may increase the analgesic activities of Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Benzphetamine.
OsanetantOsanetant may decrease the stimulatory activities of Benzphetamine.
OsimertinibThe serum concentration of Benzphetamine can be increased when it is combined with Osimertinib.
OxprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
OxycodoneBenzphetamine may increase the analgesic activities of Oxycodone.
OxymetazolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.
OxymorphoneBenzphetamine may increase the analgesic activities of Oxymorphone.
PalbociclibThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may decrease the stimulatory activities of Benzphetamine.
PargylinePargyline may increase the hypertensive activities of Benzphetamine.
ParoxetineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.
PemirolastBenzphetamine may decrease the sedative activities of Pemirolast.
PenbutololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentazocineBenzphetamine may increase the analgesic activities of Pentazocine.
PentobarbitalThe metabolism of Benzphetamine can be increased when combined with Pentobarbital.
PerospironePerospirone may decrease the stimulatory activities of Benzphetamine.
PerphenazinePerphenazine may decrease the stimulatory activities of Benzphetamine.
PethidineBenzphetamine may increase the analgesic activities of Pethidine.
PhenelzinePhenelzine may increase the hypertensive activities of Benzphetamine.
PhenindamineBenzphetamine may decrease the sedative activities of Phenindamine.
PheniprazinePheniprazine may increase the hypertensive activities of Benzphetamine.
PheniramineBenzphetamine may decrease the sedative activities of Pheniramine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Benzphetamine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Benzphetamine.
PhenobarbitalThe metabolism of Benzphetamine can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Benzphetamine.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benzphetamine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Benzphetamine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Benzphetamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Benzphetamine.
PhenytoinThe metabolism of Benzphetamine can be increased when combined with Phenytoin.
PimozidePimozide may decrease the stimulatory activities of Benzphetamine.
PindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PipamperonePipamperone may decrease the stimulatory activities of Benzphetamine.
PipotiazinePipotiazine may decrease the stimulatory activities of Benzphetamine.
PirlindolePirlindole may increase the hypertensive activities of Benzphetamine.
PivhydrazinePivhydrazine may increase the hypertensive activities of Benzphetamine.
PosaconazoleThe metabolism of Benzphetamine can be decreased when combined with Posaconazole.
PractololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.
PrimidoneThe metabolism of Benzphetamine can be increased when combined with Primidone.
ProcaterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Procaterol.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Benzphetamine.
PromazinePromazine may decrease the stimulatory activities of Benzphetamine.
PromethazineBenzphetamine may decrease the sedative activities of Promethazine.
PropericiazinePropericiazine may decrease the stimulatory activities of Benzphetamine.
PropranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
ProtriptylineProtriptyline may increase the stimulatory activities of Benzphetamine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pseudoephedrine.
QuazepamThe serum concentration of Benzphetamine can be increased when it is combined with Quazepam.
QuetiapineQuetiapine may decrease the stimulatory activities of Benzphetamine.
RacepinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.
RanitidineBenzphetamine may decrease the sedative activities of Ranitidine.
RanolazineThe metabolism of Benzphetamine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypertensive activities of Benzphetamine.
RemifentanilBenzphetamine may increase the analgesic activities of Remifentanil.
RemoxiprideRemoxipride may decrease the stimulatory activities of Benzphetamine.
ReserpineReserpine may decrease the stimulatory activities of Benzphetamine.
RifabutinThe metabolism of Benzphetamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Benzphetamine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Benzphetamine can be increased when combined with Rifapentine.
RisperidoneRisperidone may decrease the stimulatory activities of Benzphetamine.
RitodrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine.
RitonavirThe metabolism of Benzphetamine can be decreased when combined with Ritonavir.
Roxatidine acetateBenzphetamine may decrease the sedative activities of Roxatidine acetate.
SafrazineSafrazine may increase the hypertensive activities of Benzphetamine.
SaquinavirThe metabolism of Benzphetamine can be decreased when combined with Saquinavir.
SelegilineSelegiline may increase the hypertensive activities of Benzphetamine.
SertindoleSertindole may decrease the stimulatory activities of Benzphetamine.
SertralineThe metabolism of Benzphetamine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Benzphetamine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Benzphetamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Benzphetamine can be increased when it is combined with Simeprevir.
SorafenibThe metabolism of Benzphetamine can be decreased when combined with Sorafenib.
SotalolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
Spaglumic AcidBenzphetamine may decrease the sedative activities of Spaglumic Acid.
St. John's WortThe serum concentration of Benzphetamine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Benzphetamine can be increased when it is combined with Stiripentol.
SufentanilBenzphetamine may increase the analgesic activities of Sufentanil.
SulfisoxazoleThe metabolism of Benzphetamine can be decreased when combined with Sulfisoxazole.
SulpirideSulpiride may decrease the stimulatory activities of Benzphetamine.
SynephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Synephrine.
TapentadolBenzphetamine may increase the analgesic activities of Tapentadol.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Benzphetamine.
TelaprevirThe metabolism of Benzphetamine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Benzphetamine can be decreased when combined with Telithromycin.
TerbutalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline.
TerfenadineBenzphetamine may decrease the sedative activities of Terfenadine.
TesmilifeneBenzphetamine may decrease the sedative activities of Tesmilifene.
TetryzolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tetryzoline.
ThioproperazineThioproperazine may decrease the stimulatory activities of Benzphetamine.
ThioridazineThioridazine may decrease the stimulatory activities of Benzphetamine.
ThiotepaThe metabolism of Benzphetamine can be decreased when combined with Thiotepa.
ThiothixeneThiothixene may decrease the stimulatory activities of Benzphetamine.
ThonzylamineBenzphetamine may decrease the sedative activities of Thonzylamine.
TianeptineTianeptine may increase the stimulatory activities of Benzphetamine.
TiclopidineThe metabolism of Benzphetamine can be decreased when combined with Ticlopidine.
TimololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.
TocilizumabThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.
ToloxatoneToloxatone may increase the hypertensive activities of Benzphetamine.
TramadolBenzphetamine may increase the analgesic activities of Tramadol.
TranilastBenzphetamine may decrease the sedative activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benzphetamine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Benzphetamine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Benzphetamine.
TrimipramineTrimipramine may increase the stimulatory activities of Benzphetamine.
TripelennamineBenzphetamine may decrease the sedative activities of Tripelennamine.
TriprolidineBenzphetamine may decrease the sedative activities of Triprolidine.
TyramineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tyramine.
VenlafaxineThe metabolism of Benzphetamine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Benzphetamine can be decreased when combined with Verapamil.
Vitamin CThe serum concentration of Benzphetamine can be decreased when it is combined with Vitamin C.
VoriconazoleThe metabolism of Benzphetamine can be decreased when combined with Voriconazole.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Benzphetamine.
ZotepineZotepine may decrease the stimulatory activities of Benzphetamine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Benzphetamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613 ]
  2. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. [PubMed:8486332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Bumpus NN, Sridar C, Kent UM, Hollenberg PF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos. 2005 Jun;33(6):795-802. Epub 2005 Mar 15. [PubMed:15769884 ]
  2. Shebley M, Kent UM, Ballou DP, Hollenberg PF: Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52. doi: 10.1124/dmd.108.024661. Epub 2009 Jan 14. [PubMed:19144770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
References
  1. Kanaeva IP, Nikityuk OV, Davydov DR, Dedinskii IR, Koen YM, Kuznetsova GP, Skotselyas ED, Bachmanova GI, Archakov AI: Comparative study of monomeric reconstituted and membrane microsomal monooxygenase systems of the rabbit liver. II. Kinetic parameters of reductase and monooxygenase reactions. Arch Biochem Biophys. 1992 Nov 1;298(2):403-12. [PubMed:1416971 ]
  2. Matsumoto T, Emi Y, Kawabata S, Omura T: Purification and characterization of three male-specific and one female-specific forms of cytochrome P-450 from rat liver microsomes. J Biochem. 1986 Nov;100(5):1359-71. [PubMed:2434473 ]
  3. Kojima H, Takahashi K, Sakane F, Koyama J: Purification and characterization of NADPH-cytochrome c reductase from porcine polymorphonuclear leukocytes. J Biochem. 1987 Nov;102(5):1083-8. [PubMed:3125159 ]
  4. Dutton DR, McMillen SK, Parkinson A: Purification of rat liver microsomal cytochrome P-450b without the use of nonionic detergent. J Biochem Toxicol. 1988 Summer;3:131-45. [PubMed:3148724 ]
  5. Halpert JR, Miller NE, Gorsky LD: On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403. [PubMed:3924914 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23